Physician profile
Daniel Epshtein
NPI 1750763769
$42,517.01
in general payments reported to CMS, 2019-2025
22 companies · $7,468 in 2025
The $7,468 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,608 · 2020: $4,417 · 2021: $1,854 · 2022: $5,014 · 2023: $3,349 · 2024: $14K · 2025: $7,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $6,906 · Food and Beverage: $3,803 · Travel and Lodging: $1,354 · Honoraria: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,775.00 |
| Consulting Fee | $6,906.45 |
| Food and Beverage | $3,802.52 |
| Travel and Lodging | $1,354.22 |
| Honoraria | $786.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $15,958.14 | 2019-2025 | Clarus, Cirrus Hd-Oct, Forum |
| Tarsus Pharmaceuticals, INC. | $15,418.57 | 2024-2025 | Xdemvy |
| Allergan, INC. | $1,498.87 | 2019-2021 | |
| Abbvie INC. | $1,436.83 | 2022-2023 | |
| Horizon Therapeutics Plc | $1,305.70 | 2022-2023 | Tepezza |
| Regeneron Pharmaceuticals, INC. | $1,264.05 | 2021-2024 | Eylea |
| Oyster Point Pharma, INC. | $1,017.08 | 2022-2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $910.95 | 2024-2025 | |
| Immunogen, INC. | $817.00 | 2023 | Elahere |
| Novartis Pharmaceuticals Corporation | $569.38 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $511.66 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $483.69 | 2019-2020 | |
| Alcon Vision LLC | $382.24 | 2019-2025 | Hydrus Microstent, Voyager Dslt |
| Astellas Pharma US INC | $226.24 | 2024-2025 | Izervay |
| Topcon Healthcare, INC. | $186.99 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $131.77 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.01 | 2019 | |
| Harrow Eye, LLC | $98.86 | 2025 | Vevye |
| Astellas Pharma Global Development | $60.86 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $52.04 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sight Sciences, INC. | $29.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Epshtein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.